Tufts University's Center for the Study of Drug Development updated its widely cited--and oft-disputed--estimates for how much it costs to take a drug from the lab to the pharmacy, tabbing the figure at about $2.6 billion. That number, averaged from 106 randomly selected products from 10 pharma companies, is 8.5% higher than the result of Tufts' prior survey, released in 2014. More
@FierceBiotech: Corvus shoots for $80M in an IPO to support its immuno-oncology pipeline. News | Follow @FierceBiotech
@JohnCFierce: Interesting to think that pointing out what Trump got wrong could become a full-time job for the next 4 years. More | Follow @JohnCFierce
> Belgian biotech Tigenix raised about $26 million in a private placement to support its in-development treatment for bowel disease. Story
> NantKwest ($NK) said it will have to restate its last two quarterly financial disclosures after identifying an accounting error related to stock compensation for Chairman and CEO Patrick Soon-Shiong. Item
Medical Device News
@FierceMedDev: FDA loss in Vascular Solution off-label promotion case foreshadowed Amarin settlement, Artlce | Follow @FierceMedDev
@VarunSaxena2: Hmmm... all the media bumpkins can say Rubio won again. This is all you need to know. | Follow @VarunSaxena2
@EmilyWFierce: Apple plots smartphone-based medical device application for Apple Watch. Article | Follow @EmilyWFierce
> Boston Sci wins FDA approval of ablation catheter to treat atrial flutter. Story
Pharma News
@FiercePharma: BeiGene approved to start China leg of global BTK inhibitor trial. Story | Follow @FiercePharma
@EricPFierce: Vertex, committed to continuous manufacturing, has Hovione build plant to complement the one it already has. Story | Follow @EricPFierce
@CarlyHFierce: Perrigo execs collect $2.75M in bonuses for fending off Mylan takeover. More | Follow @CarlyHFierce
> EMA puts Gilead's Zydelig under the lens after deaths crop up in trials. Article